Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000226801 | SCV000289532 | uncertain significance | Primary dilated cardiomyopathy | 2022-11-28 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 240651). This variant has not been reported in the literature in individuals affected with NEBL-related conditions. This variant is present in population databases (rs746298728, gnomAD 0.009%). This sequence change replaces isoleucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 987 of the NEBL protein (p.Ile987Val). |
Ambry Genetics | RCV004827768 | SCV005457556 | uncertain significance | not specified | 2024-12-07 | criteria provided, single submitter | clinical testing | The c.2959A>G (p.I987V) alteration is located in exon 28 (coding exon 28) of the NEBL gene. This alteration results from a A to G substitution at nucleotide position 2959, causing the isoleucine (I) at amino acid position 987 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |